Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Prodrome Sciences USA, LLC
WARNING LETTER
•Prodrome Sciences USA, LLC•January 10, 2025

Prodrome Sciences USA, LLC – FDA Warning Letter, Jan 10, 2025

Record Details

Prodrome Sciences USA, LLC received a Warning Letter from the FDA following an inspection conducted between December 17, 2024, and January 10, 2025. The letter addresses significant violations concerning the company"s clinical investigation (Protocol Pro‐040‐Plasm‐01) of the product ProdromeNeuro™ Oil, which involved 29 human subjects. The primary issue identified was Prodrome Sciences" failure to submit an Investigational New Drug (IND) application before initiating this clinical study. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR Part 312, an IND is required for clinical investigations of products intended as drugs. While Prodrome Sciences argued ProdromeNeuro™ Oil was a dietary supplement, the FDA determined, based on the study design and inclusion criteria for subjects with mild to moderate dementia, that the product was investigated for use in the treatment of a disease, thus classifying it as a drug. The FDA deemed the company"s submitted corrective and preventive action plan inadequate. Prodrome Sciences must provide a more comprehensive response, detailing how they will ascertain when IND regulations apply to future clinical investigations. Furthermore, they need to outline specific procedures for developing and implementing compliance measures for any future studies requiring an IND. This is crucial to ensure the protection of human subjects and adherence to regulatory standards.

Company
Prodrome Sciences USA, LLC
Inspection date
January 10, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Brittany L. Garr-Colón
  • Dayan B. Goodenowe
  • David C. Burrow (Director )
View Company Profile

ID · 5dbe5e22-942b-482b-a753-c84dfa82e0b2

Violation Codes10
21 CFR 31221 CFR 312.2(a)21 CFR 312.20(a)21 CFR 312.20(b)21 CFR 312.40(a)21 U.S.C. 355FD&C Act 505FD&C Act 201(g)(1)21 U.S.C. 321(g)(1)21 CFR 312.40

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Prodrome Sciences USA, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.